Clinical Trial: Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Temozolomide or Dacarbazine-based Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Brief Summary: Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor
Detailed Summary:
Sponsor: Peking Union Medical College Hospital
Current Primary Outcome: overall response rate [ Time Frame: up to 12 months ]
Original Primary Outcome: Progression free survival [ Time Frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months ]
Current Secondary Outcome:
- progression free survival [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months ]
- toxicities [ Time Frame: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 ]
Original Secondary Outcome: overall survival [ Time Frame: From date of treatment until the date of death, assessed up to 5 years ]
Information By: Peking Union Medical College Hospital
Dates:
Date Received: April 29, 2013
Date Started: April 2013
Date Completion:
Last Updated: April 12, 2017
Last Verified: April 2017
